The DAC system and associations with multiple myeloma
Enrique M Ocio1, Jesús F San Miguel
1University Hospital of Salamanca, Salamanca, Spain.
Investigational New Drugs
|December 2, 2010
Summary
Histone deacetylase inhibitors (HDACi) show preclinical promise against multiple myeloma (MM) by inducing apoptosis and affecting the tumor microenvironment. However, their clinical efficacy as monotherapy is limited, necessitating combination treatments for relapsed/refractory MM patients.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Multiple myeloma (MM) remains a significant challenge, with most patients experiencing relapse, highlighting the need for novel therapeutic strategies.
- Deacetylases (DACs) play a crucial role in cancer progression by modifying histones and non-histone proteins, and their overexpression in tumors like MM warrants targeted inhibition.
Purpose of the Study:
- To review the rationale and current status of deacetylase inhibitors (DACi) as a targeted therapy for multiple myeloma (MM).
- To explore the mechanisms of action and clinical efficacy of DACi in MM, both as monotherapy and in combination regimens.
Main Methods:
- Review of preclinical and clinical studies on DACi in multiple myeloma.
- Analysis of the molecular mechanisms underlying DACi activity, including effects on apoptosis, cell cycle, tumor microenvironment, and bone disease.
- Evaluation of clinical trial data for DACi, focusing on monotherapy and combination therapies.
Main Results:
- Preclinical studies demonstrate exciting antimyeloma activity of DACi through apoptosis induction, cell cycle arrest (p21 upregulation), interference with plasma cell-microenvironment interactions, and inhibition of angiogenesis.
- DACi have shown a protective role in murine models against myeloma bone disease.
- Clinical activity of DACi as monotherapy in relapsed/refractory MM patients has been modest, prompting investigation into combination therapies.
Conclusions:
- DACi represent a promising class of targeted agents for MM, with established preclinical efficacy and multiple mechanisms of action.
- Combination strategies, particularly with bortezomib or lenalidomide and dexamethasone, are showing positive preliminary results and are being advanced clinically for MM treatment.
